Pathogenic Study of Adult Immune Enteropathies

Study Purpose

The study focuses the mechanisms underlying the loss of intestinal homeostasis in celiac disease, refractory celiac disease and other immune diseases such as monogenic enteropathy, inflammatory bowel diseases or drug induced intestinal diseases. Mechanisms of transformation of lymphocytes leading to onset of lymphomatous complications of immune enteropathies will be investigated. Mechanisms of loss of hepatic lymphocytic homeostasis will also be assessed in liver associated diseases.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Yes
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

- 18 years or over - affiliated to social insurance - signed informed consent

Exclusion Criteria:

- pregnancy - under guardianship - not able to sign informed consent

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04280510
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Institut National de la Santé Et de la Recherche Médicale, France
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Georgia MALAMUT, MD, PhD
Principal Investigator Affiliation APHP, Université de Paris (Université Paris Descartes)
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

OtherOther
Overall Status Not yet recruiting
Countries France
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Celiac Disease, Autoimmune Enteropathy, Inflammatory Bowel Diseases
Arms & Interventions

Arms

: Active coeliac patients

Patients with active coeliac disease

: Treated coeliac patients

Patients with coeliac disease on gluten free diet

: Sprue type I

Patients with refractory coeliac disease of type I

: Sprue type II

Patients with refractory coeliac disease of type II

: Intestinal Lymphoproliferations

Patients with intestinal lymphoproliferations

: Non coeliac enteropathies

Patients with non coeliac immune-mediated enteropathy

: Patients without neoplastic or inflammatory intestinal disease

Patients without neoplastic or inflammatory intestinal disease

Interventions

Genetic: - Blood sample collection; gastrointestinal biopsy

Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Hôpital Beaujon, Clichy, France

Status

Address

Hôpital Beaujon

Clichy, , 92110

Site Contact

Yoram Bouhnik, MD, PhD

yoram.bouhnik@aphp.fr

33 1 58 41 41 76

Hôpital Henri Mondor, Créteil, France

Status

Address

Hôpital Henri Mondor

Créteil, , 94010

Site Contact

Iradj Sobhani, MD, PhD

iradj.sobhani@aphp.fr

33 1 58 41 41 76

Hôpital Bicêtre, Le Kremlin Bicêtre, France

Status

Address

Hôpital Bicêtre

Le Kremlin Bicêtre, , 94270

Site Contact

Franck Carbonnel, MD, PhD

franck.carbonnel@aphp.fr

33 1 58 41 41 76

Hôpital Saint Louis, Paris, France

Status

Address

Hôpital Saint Louis

Paris, , 75010

Site Contact

Matthieu ALLEZ, MD, PhD

matthieu.allez@aphp.fr

33 1 58 41 41 76

Hôpital Saint Antoine, Paris, France

Status

Address

Hôpital Saint Antoine

Paris, , 75012

Site Contact

Laurent Beaugerie, MD, PhD

georgia.malamut@aphp.fr

33 1 58 41 41 76

Hôpital Cochin, Paris, France

Status

Address

Hôpital Cochin

Paris, , 75014

Site Contact

Georgia Malamut, MD, PhD

georgia.malamut@aphp.fr

33 1 58 41 41 76

The content provided by the Celiac Disease Foundation on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation. For a full description of terms please refer to: Privacy Policy and Terms of Use.